Sector: Biological Products, (No Diagnostic Substances) · Industry: Drug Manufacturers - Specialty & Generic · Exchange: Nasdaq
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Headquarters: Oakville, ON, US · Employees: 18 · Website: https://www.cardiolrx.com
Cardiol Therapeutics Inc. (CRDL) is a publicly traded company in the Biological Products, (No Diagnostic Substances) sector (Drug Manufacturers - Specialty & Generic), listed on Nasdaq. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.
Search companies · Macro trends · Industries · Product categories · Baskets